FDA Approves First-of-Its-Kind Chronic Hepatitis B Treatment

The United States Food and Drug Administration has officially approved Hibsago, also known as bepirovirsen, as a new treatment option for adults living with chronic hepatitis B. This medication is designed to be used in combination with existing antiviral therapies. It marks a significant milestone as the first treatment of its kind to receive regulatory approval for this specific condition. Chronic hepatitis B is a long-term liver infection caused by the hepatitis B virus, or HBV. The virus can lead to serious health complications if left unmanaged over many years. Patients often require long-term medication to keep the virus suppressed and prevent further liver damage. Hibsago aims to change this standard of care by providing a new approach to viral control. The approval is specifically for adults who do not have cirrhosis and have been taking standard HBV antiviral therapy for at least six months. These patients must also show suppressed levels of the virus in their blood. Wendy Carter, the Acting Director of the Office of Infectious Diseases at the FDA, noted the importance of this development. She explained that Hibsago offers a new way for some patients to maintain control of the virus even after their primary chronic HBV treatment has ended. This could potentially reduce the long-term burden of daily medication for those who qualify. Clinical trials provided the data necessary to support this approval. Across two separate studies, researchers found that 24 percent of patients who received Hibsago were able to meet the requirements to stop their existing medicine. In contrast, none of the patients who received a placebo were able to do so. The results were measured 24 weeks after the patients stopped all hepatitis B treatment. During this follow-up period, 19 percent of those who received Hibsago maintained control of the virus. Furthermore, a specific protein that signals the presence of a hepatitis B infection could not be detected in their blood. This suggests that the treatment may help the body achieve a more sustained response. Medical professionals will continue to monitor patients throughout the course of their therapy. The FDA has provided specific guidelines for the use of Hibsago in accordance with approved drug labeling. This ensures that the medication is administered safely and effectively to the appropriate patient population. The introduction of this therapy represents a notable advance for individuals managing this serious disease. Future efforts will likely focus on long-term outcomes for patients who successfully transition off their traditional antiviral medications.